Status:
UNKNOWN
Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency
Lead Sponsor:
Affiliated Hospital of Nantong University
Conditions:
Primary Ovarian Insufficiency
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
Resveratrol is a natural plant antitoxin widely found in grapes, mulberries, and other plants. Resveratrol mediates a variety of pharmacological effects, including antioxidant, immunomodulatory, anti-...
Detailed Description
The preliminary experiments of the investigators' group examined the gene expression in ovarian granulosa cells of POI patients and normal controls using high-throughput sequencing technology. The inv...
Eligibility Criteria
Inclusion
- Amenorrhea or oligomenorrhea at least 4 months and two (\>4 weeks interval) basal FSH≥10mIU/ml；
- The women aged \<40 years old；
- Informed consent, voluntary experiment.
Exclusion
- Pregnant and lactating patients;
- Patients with endometriosis, adenomyosis, endometrial lesions (submucosal fibroids, endometrial polyps, etc.), uterine fibroids\>4 cm or hysterectomy;
- Patients with adrenal cortical hyperplasia or tumour；
- Ovarian neoplasms patients；
- Hydrosalpinx patients；
- Hyperprolactinemia patients；
- Patients who are participating in other clinical trials or have participated in other clinical trials within the past three months;
- Patients with a suspected or real history of alcohol and drug abuse;
- Known allergy to the investigational drug or its components;
- Other patients were deemed unsuitable for participation in this trial by the investigator.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05410093
Start Date
February 1 2022
End Date
July 31 2024
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
B ultrasound
Nantong, Jiangsu, China, 226000